Select Language
Free Registration

GPRC5B

GPRC5B Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag & Flag Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
GPB-H52D7
Human
HEK293
Human GPRC5B Protein, Flag,His Tag (Detergent)
Total: 1
  • 1

GPRC5B Background

This gene encodes a member of the type 3 G protein-coupled receptor family. Members of this superfamily are characterized by a signature 7-transmembrane domain motif. The encoded protein may modulate insulin secretion and increased protein expression is associated with type 2 diabetes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2015]

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AtaciceptTACI-IgPhase 3 ClinicalZymogenetics IncGlomerulonephritis, IGA; Kidney Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Urinary Bladder Diseases; Lupus Erythematosus, Systemic
Details
ZigakibartBION-1301Phase 3 ClinicalAduro Biotech IncGlomerulonephritis, IGA; Proteinuria; Multiple Myeloma
Details
PovetaciceptALPN-303; ALPN 30xPhase 3 ClinicalAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis
Details
SibeprenlimabVIS-649Phase 3 ClinicalVisterra IncGlomerulonephritis, IGA; Glomerulonephritis
Details
IM-21IM21; IM-21Phase 1 ClinicalBeijing Yimiao Medical Technology Co LtdMultiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)Phase 1 ClinicalEugia Pharma Specialities Ltd, Actavis IncMultiple Myeloma
Details
anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital）Phase 1 ClinicalMassachusetts General HospitalMultiple Myeloma
Details
AUR-200AUR-200; AUR200Phase 1 ClinicalThunderbolt Pharma IncAutoimmune Diseases
Details
RO-7297089RO-7297089; AFM-26; RG-6296Phase 1 ClinicalGenentech IncMultiple Myeloma
Details
APRIL CAR-T Cell therapy (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)ClinicalHuazhong University Of Science And TechnologyMultiple Myeloma
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
TelitaciceptRCT-18; RC-18; RCT18; RC18ApprovedRemeGen Co LtdMainland ChinaLupus Erythematosus, SystemicRemeGen Co Ltd2021-03-09Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Nephrosis; Immunoglobulin G4-Related Disease; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland